Cancer Cachexia Market revenue to reach USD 4.5 Billion by 2036, says Research Nester
December 07, 2023 06:00 ET
|
Research Nester
New York, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cancer cachexia market size is predicted to grow at a CAGR of over 4.5% from 2024 to 2036. The market is projected to garner a revenue of USD...
RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
January 23, 2023 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
March 23, 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Cancer Anorexia Market Insights Report 2021 - Major Players are NGM Biopharmaceuticals, Artelo Biosciences and Helsinn Healthcare
April 08, 2021 07:04 ET
|
Research and Markets
Dublin, April 08, 2021 (GLOBE NEWSWIRE) -- The "Cancer Anorexia - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.This...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
February 03, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
September 10, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced...
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
April 09, 2019 09:35 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies Appoints New Chief Executive Officer
January 08, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the...
AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
May 15, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has reached a long-term...
RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018
January 08, 2018 08:45 ET
|
RespireRX Pharmaceuticals Inc.
CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...